Ástralía - enska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: docusate sodium; hypromellose; sodium lauryl sulfate; sucrose; silicified microcrystalline cellulose; crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate cipla is indicated as an adjunct to diet in the treatment of:,- hypercholesterolaemia;,- types ii, iii, iv and v dyslipidaemia;,- dyslipidaemia assocated with type 2 diabetes.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: docusate sodium; hypromellose; sodium lauryl sulfate; sucrose; silicified microcrystalline cellulose; crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate is indicated as an adjunct to diet in the treatment of:,- hypercholesterolaemia;,- types ii, iii, iv and v dyslipidaemia;,- dyslipidaemia assocated with type 2 diabetes.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Ísrael - enska - Ministry of Health

abic marketing ltd, israel - lorcaserin hydrochloride hemihydrate - film coated tablets - lorcaserin hydrochloride hemihydrate 10.4 mg - lorcaserin - belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (bmi) of:• 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)

Ísrael - enska - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 10 mg - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.